RxDoctor Payments Data

Asad Butt, MD

Family Medicine · Bronx, NYNPI 1679033930

Payments from drug & device makers

$669in general payments, 2019–2025

Across 25 payments — averaging $26.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$125
  • AstraZeneca$121
  • Novo Nordisk$111
  • Exact Sciences$104
  • Beigene USA, Inc.$49
  • Lilly USA, LLC$36
  • plus $122 from 7 others

What the payments were for

  • Food & beverage$669100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$669 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$23,948
Medicare patients
91
Services billed
234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin73$89,203
JanumetSitagliptin Phos/Metformin Hcl38$53,379
BiktarvyBictegrav/Emtricit/Tenofov Ala11$43,849
EliquisApixaban43$42,736
JanuviaSitagliptin Phosphate31$35,162
OzempicSemaglutide23$32,755
TrulicityDulaglutide23$30,724
FarxigaDapagliflozin Propanediol21$29,371
EntrestoSacubitril/Valsartan28$15,990
MounjaroTirzepatide12$12,902
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$11,730
VascepaIcosapent Ethyl23$7,236
Spiriva RespimatTiotropium Bromide12$6,565
SymbicortBudesonide/Formoterol Fumarate13$4,237
Atorvastatin Calcium430$4,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$29$95,76885 claims
Lilly USA, LLCTrulicity, Mounjaro$36$43,62735 claims
AstraZenecaFarxiga, Symbicort$121$33,60834 claims
Novo NordiskOzempic$111$32,75523 claims
GSKTrelegy Ellipta$15$11,73013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →